J D Brunzell

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Clinical practice. Hypertriglyceridemia
    John D Brunzell
    Department of Medicine, Division of Metabolism, Endocrinology, and Nutrition, and the Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle, USA
    N Engl J Med 357:1009-17. 2007
  2. ncbi Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment
    A Zambon
    Department of Medicine, University of Washington, Seattle, WA 98195 6426, USA
    Circulation 103:792-8. 2001
  3. ncbi Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men
    J Q Purnell
    Department of Medicine, University of Washington, Seattle 98195, USA
    J Clin Endocrinol Metab 85:977-82. 2000
  4. ncbi Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density
    A Zambon
    Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, Wash 98195 6426, USA
    Circulation 99:1959-64. 1999
  5. ncbi Use of niacin, statins, and resins in patients with combined hyperlipidemia
    B G Brown
    Department of Medicine, University of Washington School of Medicine, Seattle 98195, USA
    Am J Cardiol 81:52B-59B. 1998
  6. ncbi A hepatic lipase gene promoter polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women
    M C Carr
    Department of Medicine, Divisions of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle 98195 6426, USA
    Arterioscler Thromb Vasc Biol 19:2701-7. 1999
  7. ncbi The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity
    M C Carr
    Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, Washington 98195, USA
    J Clin Endocrinol Metab 86:2831-7. 2001
  8. ncbi Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy
    A Zambon
    Department of Medicine, University of Washington, Seattle, WA 98195 6426, USA
    J Intern Med 259:401-9. 2006
  9. ncbi Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex
    E M Wijsman
    Department of Medicine, School of Medicine, University of Washington, Seattle 98195 7720, USA
    Arterioscler Thromb Vasc Biol 18:215-26. 1998
  10. ncbi Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial
    J Q Purnell
    Department of Medicine, University of Washington, Seattle 98195, USA
    JAMA 280:140-6. 1998

Detail Information

Publications74

  1. ncbi Clinical practice. Hypertriglyceridemia
    John D Brunzell
    Department of Medicine, Division of Metabolism, Endocrinology, and Nutrition, and the Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle, USA
    N Engl J Med 357:1009-17. 2007
  2. ncbi Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment
    A Zambon
    Department of Medicine, University of Washington, Seattle, WA 98195 6426, USA
    Circulation 103:792-8. 2001
    ..We tested the hypothesis that subjects with the CC genotype and a more atherogenic lipid profile experience the greatest CAD regression from these favorable effects...
  3. ncbi Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men
    J Q Purnell
    Department of Medicine, University of Washington, Seattle 98195, USA
    J Clin Endocrinol Metab 85:977-82. 2000
    ..In summary, in men undergoing diet-induced weight loss, only loss of IAF was found to be associated with a reduction in HL, which is associated with beneficial effects on lipid levels...
  4. ncbi Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density
    A Zambon
    Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, Wash 98195 6426, USA
    Circulation 99:1959-64. 1999
    ..This study examines the relationship among LDL density, hepatic lipase (HL), and CAD progression, identifying a new biological mechanism for the favorable effects of lipid-altering therapy...
  5. ncbi Use of niacin, statins, and resins in patients with combined hyperlipidemia
    B G Brown
    Department of Medicine, University of Washington School of Medicine, Seattle 98195, USA
    Am J Cardiol 81:52B-59B. 1998
    ..This improvement is associated with therapeutic reduction of LDL-C and elevation of HDL-C, but also appears to be associated with drug-induced improvement in LDL buoyancy...
  6. ncbi A hepatic lipase gene promoter polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women
    M C Carr
    Department of Medicine, Divisions of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle 98195 6426, USA
    Arterioscler Thromb Vasc Biol 19:2701-7. 1999
    ..003). We conclude that the LIPC promoter A allele attenuates the increase in HL activity due to IAF in premenopausal women...
  7. ncbi The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity
    M C Carr
    Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, Washington 98195, USA
    J Clin Endocrinol Metab 86:2831-7. 2001
    ..The higher HL activity in men affects both LDL and HDL heterogeneity and may contribute to the gender difference in cardiovascular risk...
  8. ncbi Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy
    A Zambon
    Department of Medicine, University of Washington, Seattle, WA 98195 6426, USA
    J Intern Med 259:401-9. 2006
    ....
  9. ncbi Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex
    E M Wijsman
    Department of Medicine, School of Medicine, University of Washington, Seattle 98195 7720, USA
    Arterioscler Thromb Vasc Biol 18:215-26. 1998
    ..Explanations for the differences in results between these studies include genetic heterogeneity, differences in clinical phenotype used to select the pedigrees, and ascertainment bias...
  10. ncbi Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial
    J Q Purnell
    Department of Medicine, University of Washington, Seattle 98195, USA
    JAMA 280:140-6. 1998
    ..Intensive treatment of type 1 diabetes results in greater weight gain than conventional treatment...
  11. ncbi Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women
    M C Carr
    Division of Metabolism, University of Washington, Seattle, USA
    Arterioscler Thromb Vasc Biol 22:667-73. 2002
    ..Thus, HL is an important determinant of sdLDL and HDL2 cholesterol in normal physiological states as well as in the pathogenesis of various disease processes...
  12. ncbi Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes
    S D Sibley
    Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle 98195, USA
    Diabetes Care 22:1165-70. 1999
    ..This population study examines the relationship between LDL density and persistent albuminuria in subjects with type 1 diabetes at the end of the Diabetes Control and Complications Trial (DCCT)...
  13. ncbi Low-density lipoprotein particle size loci in familial combined hyperlipidemia: evidence for multiple loci from a genome scan
    Michael D Badzioch
    Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, USA
    Arterioscler Thromb Vasc Biol 24:1942-50. 2004
    ....
  14. ncbi Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
    J Q Purnell
    Department of Medicine, University of Washington, Seattle 98195, USA
    AIDS 14:51-7. 2000
    ..Whether the lipid abnormalities result from changes in metabolism after an improvement in HIV status or are partly attributable to the effects of protease inhibitor use is unknown...
  15. ncbi Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia
    Amir F Ayyobi
    Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, Washington 98195, USA
    Am J Cardiol 92:27J-33J. 2003
    ..Treatment of the dyslipidemia associated with type 2 diabetes and FCHL with a combination of a statin and a thiazolidinedione or niacin offers the most comprehensive modality to correct the various lipid abnormalities...
  16. ncbi Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study
    M A Austin
    Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle 98195 7236, USA
    Circulation 101:2777-82. 2000
    ..The purposes of this study were to estimate 20-year total and CVD mortality risk among relatives in these families and to evaluate plasma triglyceride as a predictor of death...
  17. ncbi Changes in LDL density across the menopausal transition
    M C Carr
    Department of Medicine, University of Washington, Seattle 98195 6426, USA
    J Investig Med 48:245-50. 2000
    ..Characterization of lipoprotein levels and LDL buoyancy across the stages of the menopausal transition has yet to be reported...
  18. ncbi Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease
    A Zambon
    Department of Medicine, University of Washington, Seattle, WA 98195-6426, USA
    J Intern Med 259:473-80. 2006
    ..Therefore, in genetic dyslipidaemias elevated apo B levels and reduced apo AI levels (or increased apo B/AI ratio) differ and predict premature coronary artery disease...
  19. ncbi Hepatic lipase as a focal point for the development and treatment of coronary artery disease
    A Zambon
    Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, USA
    J Investig Med 49:112-8. 2001
    ....
  20. ncbi Linkage of low-density lipoprotein size to the lipoprotein lipase gene in heterozygous lipoprotein lipase deficiency
    J E Hokanson
    Divisions of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle WA 98195 6426, USA
    Am J Hum Genet 64:608-18. 1999
    ..This study also demonstrates a successful strategy of genotypic specific adjustment of complex traits in mapping a quantitative trait locus...
  21. ncbi Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity
    S E Kahn
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington and Department of Veterans Affairs, Puget Sound Health Care, Seattle, WA 98108, USA
    J Nutr 131:354S-60S. 2001
    ..Furthermore, the progression from normal glucose tolerance to impaired glucose tolerance and type 2 diabetes is associated with declining insulin secretion...
  22. ncbi Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer
    Jonathan Q Purnell
    Department of Medicine, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, OR 97239, USA
    J Lipid Res 47:349-55. 2006
    ..Compared with ADT, short-term TDE therapy of prostate cancer improves lipid levels without deterioration of CVD-associated inflammatory markers and may, on longer-term follow-up, improve CVD and mortality rates...
  23. ncbi Relationship of insulin sensitivity and ApoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia
    J Q Purnell
    Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA
    Arterioscler Thromb Vasc Biol 21:567-72. 2001
    ....
  24. ncbi A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity
    W S Yang
    Department of Medicine, University of Washington, Seattle 98195, USA
    Proc Natl Acad Sci U S A 92:4462-6. 1995
    ..Thus, heterozygosity for LPL promoter mutations may be one of several factors that contribute to the etiology of FCHL...
  25. ncbi Selective and independent associations of phospholipid transfer protein and hepatic lipase with the LDL subfraction distribution
    Susan J Murdoch
    Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA
    J Lipid Res 43:1256-63. 2002
    ..PLTP and LPL were positively correlated and HL was negatively correlated with HDL fractions. The results suggest that PLTP and HL may be important and independent determinants of the LDL subpopulation density distributions...
  26. ncbi Regulation of body adiposity and the problem of obesity
    M W Schwartz
    Department of Medicine, University of Washington, Seattle, USA
    Arterioscler Thromb Vasc Biol 17:233-8. 1997
    ..Since the combination of a low-fat diet with an exercise program appears to reduce the level at which body weight is regulated without active caloric restriction, this approach may be appropriate for many obese individuals...
  27. ncbi Two novel apolipoprotein A-IV variants in individuals with familial combined hyperlipidemia and diminished levels of lipoprotein lipase activity
    S S Deeb
    Department of Medicine, University of Washington, Seattle 98195, USA
    Hum Mutat 8:319-25. 1996
    ..A third previously undescribed variant (A141S) was observed in four (two homozygotes and two heterozygotes) of the 97 medical students...
  28. ncbi Ethnic differences in hepatic lipase and HDL in Japanese, black, and white Americans: role of central obesity and LIPC polymorphisms
    Molly C Carr
    Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA
    J Lipid Res 45:466-73. 2004
    ....
  29. ncbi Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome
    Darcy B Carr
    Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington 98195 6460, USA
    Diabetes 53:2087-94. 2004
    ..Of the NCEP criteria, waist circumference and triglycerides may best identify insulin resistance and visceral adiposity in individuals with a fasting plasma glucose <6.4 mmol/l...
  30. ncbi Genome-wide scan for quantitative trait loci influencing LDL size and plasma triglyceride in familial hypertriglyceridemia
    Melissa A Austin
    Department of Epidemiology and Institute for Public Health Genetics, School of Public Health and Community Medicine, University of Washington, Seattle, WA, USA
    J Lipid Res 44:2161-8. 2003
    ..These peaks were retained with adjustment for LDL size and/or HDL cholesterol. These findings, if confirmed, suggest that LDL particle size and plasma TG levels could be caused by two different genetic loci in FHTG...
  31. ncbi Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia
    Andrew N Hoofnagle
    Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    Arterioscler Thromb Vasc Biol 30:2528-34. 2010
    ..To determine whether obesity and insulin resistance associate with changes in the protein content of high-density lipoprotein (HDL) in 2 different groups of men by using targeted proteomics...
  32. ncbi LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes
    Susan J Murdoch
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA 98195, United States
    Atherosclerosis 192:138-47. 2007
    ..The apo E isoform also has a significant effect on LDL concentration in both homozygotes and heterozygotes...
  33. ncbi Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study
    Ian H De Boer
    Division of Nephrology, University of Washington, Seattle, Washington 98195, USA
    J Am Soc Nephrol 18:235-43. 2007
    ..In conclusion, waist circumference predicts the subsequent development of microalbuminuria in type 1 diabetes. In contrast, no association of waist circumference with decline in creatinine clearance was observed...
  34. ncbi Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus
    Ian H De Boer
    Division of Nephrology, University of Washington, Box 356521, 1959 NE Pacific St, Seattle, WA 98117, USA
    Arch Intern Med 168:1867-73. 2008
    ..Diabetes mellitus and hypertension are closely linked, but the long-term blood pressure effects of glucose-lowering therapy and hyperglycemia are not clear...
  35. ncbi Linkage and association analyses identify a candidate region for apoB level on chromosome 4q32.3 in FCHL families
    Ellen M Wijsman
    Division of Medical Genetics, Department of Medicine, University of Washington, 4333 Brooklyn Ave NE, Box 359460, Seattle, WA 98195 9460, USA
    Hum Genet 127:705-19. 2010
    ....
  36. ncbi 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III)
    Ian H De Boer
    Division of Nephrology, University of Washington, Seattle, WA 98117, USA
    Am J Kidney Dis 50:69-77. 2007
    ..Albuminuria is a risk factor for chronic kidney disease progression, end-stage renal disease, cardiovascular events, and mortality. Animal studies suggested that vitamin D insufficiency may contribute to the pathogenesis of albuminuria...
  37. ncbi PLTP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity
    Susan J Murdoch
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA 98195, USA
    J Lipid Res 44:1705-12. 2003
    ..71, P < 0.001). In conclusion, elevated PLTP activity in obese subjects is likely a result of increased body fat, reflected by SQF, and is influenced by NEFAs but is not directly related to insulin resistance...
  38. ncbi Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-I,A-II)
    Marian C Cheung
    Department of Medicine, University of Washington, Seattle, WA 98103, USA
    J Lipid Res 44:1552-8. 2003
    ..Furthermore, select correlations of LPL and/or HL with the apoA-I, cholesterol, and triglyceride of Lp(A-I) but not Lp(A-I,A-II) imply that the apoA-I and lipid of Lp(A-I) and Lp(A-I,A-II) are not fully equilibrated...
  39. ncbi The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat
    Delma J Nieves
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, Veterans Affairs Puget Sound Health Care System and Harborview Medical Center, University of Washington, Seattle, Washington 98108, USA
    Diabetes 52:172-9. 2003
    ..Thus an atherogenic lipoprotein profile appears to be the result primarily of an increase in IAF, perhaps via insulin resistance...
  40. ncbi Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk
    Molly C Carr
    Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle, Washington 98195 6426, USA
    J Clin Endocrinol Metab 89:2601-7. 2004
    ..The measurement of fasting glucose and apolipoprotein B, in addition to the fasting lipid profile, can help to estimate CAD risk in patients with the metabolic syndrome...
  41. ncbi Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet
    Samir S Deeb
    Divisions of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA 98195, USA
    J Lipid Res 44:1279-86. 2003
    ..The dyslipidemia with high HL activity is a potentially proatherogenic lipoprotein profile in the metabolic syndrome, in Type 2 diabetes, and in familial combined hyperlipidemia...
  42. ncbi Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia
    Amir F Ayyobi
    Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle, Wash, USA
    Arterioscler Thromb Vasc Biol 23:1289-94. 2003
    ..CONCLUSIONS: Although triglyceride and cholesterol levels are variable by lipoprotein phenotype, sdLDL and elevated plasma apolipoprotein B levels are consistent characteristics of FCHL shared by the 3 different lipoprotein phenotypes...
  43. ncbi Adipose tissue fatty acid composition in humans with lipoprotein lipase deficiency
    N F Ullrich
    Department of Medicine, University of Washington School of Medicine, Seattle 30086, USA
    J Investig Med 49:273-5. 2001
    ....
  44. ncbi Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study
    M J McNeely
    Department of Medicine, School of Medicine, University of Washington, Box 356429, Seattle, WA 98195, USA
    Atherosclerosis 159:471-81. 2001
    ..In conclusion, apoB is associated with hyperlipidemia and apoE polymorphism is associated with later onset of hyperlipidemia in FCHL...
  45. ncbi Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus
    John D Brunzell
    Department of Medicine, Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, Washington 98195-6178, USA
    Am J Med 115:24S-28S. 2003
    ..The ultimate goal of treatment in this patient population is to prevent the development and progression of coronary artery disease...
  46. ncbi Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation
    John D Brunzell
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, Northwest Lipid Laboratory, University of Washington, Seattle, Washington, USA
    J Am Coll Cardiol 51:1512-24. 2008
  47. ncbi Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex
    M Cnop
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, Veterans Affairs Puget Sound Health Care System (151) and University of Washington, 1660 S. Columbian Way, Seattle, WA 98108, USA
    Diabetologia 46:459-69. 2003
    ..Adiponectin could link intra-abdominal fat with insulin resistance and an atherogenic lipoprotein profile...
  48. ncbi Molecular basis of familial chylomicronemia: mutations in the lipoprotein lipase and apolipoprotein C-II genes
    M Reina
    Department of Medicine, University of Washington, Seattle 98195
    J Lipid Res 33:1823-32. 1992
    ..A nonsense mutation (Arg 19 Term) in the gene encoding apolipoprotein C-II (apoC-II), the cofactor of LPL, was found to underlie chylomicronemia in the sixth patient who had normal LPL but was apoC-II-deficient...
  49. ncbi Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
    John D Brunzell
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, and the Northwest Lipid Laboratory, University of Washington, Seattle, Washington, USA
    Diabetes Care 31:811-22. 2008
  50. ncbi Köbberling type of familial partial lipodystrophy: an underrecognized syndrome
    Karen L Herbst
    Department of Medicine, University of Washington, Seattle, Washington, USA
    Diabetes Care 26:1819-24. 2003
    ..The latter disorder is associated with mutations in the LMNA gene. FPLD1 is thought to be rare. Here, we report 13 subjects with FPLD1, suggesting that this syndrome is more common than previously thought...
  51. ncbi Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk
    Karen L Herbst
    Department of Medicine, University of Washington, Seattle, Washington 98195, USA
    Am J Physiol Endocrinol Metab 284:E1112-8. 2003
    ..Testosterone is therefore a potent stimulator of hepatic lipase activity, decreasing HDL-C, HDL(2), and HDL(3) as well as increasing LDL particle density changes, all associated with increased cardiovascular risk...
  52. ncbi Structural and functional consequences of missense mutations in exon 5 of the lipoprotein lipase gene
    Jonas Peterson
    Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, Box 356426, University of Washington Medical Center, Seattle, WA 98195 6426, USA
    J Lipid Res 43:398-406. 2002
    ..These results stress the importance of conformational evaluation of mutant LPL. Absence of catalytic activity does not necessarily imply that the substituted amino acid plays a specific direct role in catalysis...
  53. ncbi Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study
    Christine G Lee
    Department of Medicine, Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, Washington 98195 4626, USA
    J Clin Endocrinol Metab 94:1104-10. 2009
    ..Postmenopausal women have greater visceral adiposity compared with premenopausal women. Adipokines are associated with increased adiposity, insulin resistance, and atherosclerosis...
  54. ncbi Intra-abdominal fat accumulation is greatest at younger ages in Japanese-American adults
    Christine G Lee
    Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Diabetes Res Clin Pract 89:58-64. 2010
    ..We evaluated whether changes over 10-11 years in weight, subcutaneous abdominal fat (SQAF), and intra-abdominal fat (IAF) differ by age and contrasted age-related adiposity changes by gender...
  55. ncbi Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia
    C Daniel Meyers
    University of Washington School of Medicine, Seattle, Washington, USA
    Ann Intern Med 139:996-1002. 2003
    ..Nicotinic acid is an effective treatment for dyslipidemia, but the content of over-the-counter niacin is not federally regulated. As a result, patients may use preparations of over-the-counter niacin that do not contain free nicotinic acid...
  56. ncbi Energy balance in congenital generalized lipodystrophy type I
    Sasha Taleban
    General Clinical Research Center, University of Washington, USA
    Metabolism 57:1155-61. 2008
    ..Appetite-regulating hormone levels in CGL-1 suggest that multiple factors act to control appetite in these individuals...
  57. ncbi Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes
    Shalamar D Sibley
    Division of Endocrinology and Diabetes, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Clin Endocrinol Metab 88:3379-84. 2003
    ..DCCT-related weight gain positively correlated with subsequent IAF...
  58. ncbi Intra-abdominal fat and elevated urine albumin excretion in men with type 1 diabetes
    Shalamar D Sibley
    Department of Endocrinology and Diabetes, University of Minnesota, Mayo Medical Code 101, 420 Delaware St. SE, Minneapolis, MN 55455, USA
    Diabetes Care 30:1898-900. 2007
  59. ncbi Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy
    Dahong Yu
    GlaxoSmithKline, King of Prussia, PA 19406, USA
    Diab Vasc Dis Res 3:189-96. 2006
    ..However, the increase in IDL may be proatherogenic and must be considered when assessing the benefits of rosiglitazone...
  60. ncbi Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus
    Martin I Freed
    GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA
    Am J Cardiol 90:947-52. 2002
    ....
  61. ncbi Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans
    Chunyu Zheng
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 26:891-6. 2006
    ..CONCLUSIONS: Plasma LpL may act like an apolipoprotein to enhance the clearance of apoB lipoproteins in humans, a mechanism particularly important for intestinal lipoproteins in the postprandial state...
  62. ncbi Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial
    Jonathan Q Purnell
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon 97201, USA
    Diabetes 52:2623-9. 2003
    ..These data support the hypothesis that increased weight gain with intensive therapy might be explained, in part, by genetic traits...
  63. ncbi Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy
    Molly C Carr
    Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611 3008, USA
    Diabetes Care 28:1555-61. 2005
    ..This study was designed to assess the effect of raloxifene on serum triglycerides in postmenopausal women who have a history of increased hypertriglyceridemia with oral estrogen therapy...
  64. ncbi Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus
    Peter Libby
    Brigham and Women's Hospital, Boston, Mass, USA
    Circulation 111:3489-93. 2005
  65. ncbi Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone
    Gary F Lewis
    Department of Medicine and Physiology, Division of Endocrinology and Metabolism, University of Toronto, Ontario, Canada
    Diabetes 53:2893-900. 2004
    ....
  66. ncbi Hepatic lipase: a marker for cardiovascular disease risk and response to therapy
    Alberto Zambon
    Department of Medical and Surgical Sciences, University of Padova, Italy
    Curr Opin Lipidol 14:179-89. 2003
    ..The potential impact of genetic determinants of hepatic lipase activity in modulating both the development of coronary and carotid atherosclerosis will be discussed based on hepatic lipase proposed roles in lipoprotein metabolism...
  67. ncbi Gender and elevated albumin excretion in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort: role of central obesity
    Shalamar D Sibley
    Department of Biostatistics, University of Minnesota School of Medicine, Minneapolis, MN 55455, USA
    Am J Kidney Dis 47:223-32. 2006
    ..These relationships have been examined less thoroughly in patients with type 1 diabetes...
  68. ncbi Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications
    Marion J Franz
    Nutrition Concepts by Franz, Inc, Minneapolis, Minnesota 55439, USA
    Diabetes Care 25:148-98. 2002
  69. ncbi Evidence of linkage of HDL level variation to APOC3 in two samples with different ascertainment
    France Gagnon
    Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Hum Genet 113:522-33. 2003
    ..We also provide evidence, using the FCHL data set, for a pleiotropic effect between HDL, HDL3 and triglycerides at the APOC3 locus...
  70. ncbi Genome scan for quantitative trait loci influencing HDL levels: evidence for multilocus inheritance in familial combined hyperlipidemia
    France Gagnon
    Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Hum Genet 117:494-505. 2005
    ..0 and 2.6, respectively. Weaker evidence of linkage was also obtained for 7q32, 12q12, 14q31-32 and 16q23-24...
  71. ncbi Increased ApoB in small dense LDL particles predicts premature coronary artery disease
    John D Brunzell
    Arterioscler Thromb Vasc Biol 25:474-5. 2005
  72. ncbi Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications
    Marion J Franz
    Diabetes Care 26:S51-61. 2003
  73. ncbi Nutrition principles and recommendations in diabetes
    Marion J Franz
    Diabetes Care 27:S36-46. 2004
  74. ncbi A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al
    John D Brunzell
    Diabetes Care 28:2984-5; author reply 2985-6. 2005